GET HELP NOW

Monday, November 20, 2017

Osimertinib improves progression-free survival in Asian EGFR-mutated lung cancer patients

http://ift.tt/eA8V8J Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial.

from http://ift.tt/2Ag5z81
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Children whose mothers use marijuana are more likely to try it at younger age

When mothers use marijuana during the first 12 years of their child's life, their cannabis-using children are more likely to start at an...